SAN CARLOS, Calif., Oct. 4, 2013 /PRNewswire/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that Dr. Mike Reed, Chief Scientist, and Dr. Christina Friedrich, Chief Engineer, will present at the Japanese Society for the Study of Xenobiotics, JSSX Annual Meeting ( October 9 th – 11 th), Tokyo, Japan. Dr. Reed's talk, entitled "Application of Mechanistic Physiological Modeling in the Drug Development Process – Overview and Case Studies", will introduce key features of mechanistic physiological models (also known as quantitative systems pharmacology or PhysioPD™ models), which are deployed in Rosa's practice. Dr. Reed will use multiple case studies to illustrate the application and impact of mechanistic models in drug discovery and development. Dr. Friedrich's seminar, entitled "Introduction of a Model Qualification Method (MQM) to foster model-based drug development in the exploratory phase of R&D" will outline the procedures and key qualification criteria of Rosa's MQM. Dr. Friedrich will describe the motivation behind each criterion and its role in confirming that a model is fit for purpose; examples will illustrate how the MQM approach ensures a successful modeling project.
"We are honored to have the opportunity to speak at this very prestigious meeting," said Dr. Ron Beaver, Rosa's President and CEO.
About RosaRosa helps clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of R&D related challenges, Rosa offers customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these capabilities, Rosa's clients participate in customized model creation, testing, and research simulations, retain the models, and acquire the ability to perform model research to inform decisions and better understand implications for their drug development programs. Rosa's staff has unparalleled professional experience in applying modeling and simulation to accelerate drug development and have completed hundreds of engagements with clients in virtually all therapeutic areas. The Rosa team is unique in its breadth and depth of disease area experience, including metabolic diseases, oncology, inflammation, immune dysfunction, CNS, dermatology, and antibacterial/antiviral biology. For more information, visit www.rosaandco.com. Press Contact: Rebecca Baillie 530-661-7476 Read more news from Rosa & Co. LLC SOURCE Rosa & Co. LLC